Turn Therapeutics Discloses Going Concern Doubt, Secures $25M Loan, and Faces Significant Dilution Risk

summarizeSummary

Turn Therapeutics Inc. filed its annual report, disclosing substantial doubt about its ability to continue as a going concern due to significant losses and cash burn. The company secured a new $25 million loan facility and has an existing $85 million equity purchase agreement to address its capital needs, but faces substantial potential dilution.

check_boxKey Events

• Substantial Doubt About Going Concern

  The company's consolidated financial statements express substantial doubt about its ability to continue as a going concern due to insufficient capital to fund its drug development plans and expected cash needs beyond Q3 2026.

• Secured New $25 Million Loan Facility

  On March 23, 2026, the company entered into a Loan and Security Agreement with Avenue Capital for up to $25 million, with an initial $7 million funded on March 24, 2026. The loan bears interest at the greater of (5.50% + prime rate) or 12.25% and is secured by all company assets. The lender also received 342,857 shares at no cost and has a dilutive conversion option for up to $2.0 million of principal at 80% of the trading price.

• Ongoing $85 Million Equity Purchase Agreement

  An existing agreement with GEM allows the company to sell up to $85 million in common stock at 90% of the average daily closing price. As of December 31, 2025, $4.07 million has been raised, and a warrant for 1,192,207 shares (4% of fully diluted equity) was issued to GEM at an exercise price of $5.03.

• Significant Potential Dilution

  The company has 500,000,000 authorized common shares and 29,788,040 shares outstanding as of March 30, 2026. If all authorized shares were issued, dilution would be 1578.5%.

auto_awesomeAnalysis

Turn Therapeutics Inc.'s annual report reveals substantial doubt about its ability to continue as a going concern, driven by increasing net losses and significant cash burn. The company has secured a new $25 million loan facility from Avenue Capital, with an initial $7 million funded, but this debt bears a high interest rate and is secured by all company assets. Additionally, the lender holds a dilutive conversion option for up to $2.0 million of the principal into common stock at 80% of the trading price. The existing $85 million equity purchase agreement with GEM, under which $4.07 million has been raised, also involves sales at a discount to market price and includes a warrant for 1.19 million shares. With over 470 million authorized but unissued shares, the company faces potential dilution exceeding 1500% if all authorized shares were issued. While these financing efforts provide a temporary capital runway, they underscore the company's precarious financial position and the high cost of capital, posing a significant risk to existing shareholders.